The side effects of other antibiotics used for the
Post# of 72440
The management has made it clear that the only reason we have not proceeded with the Bril-ABSSSI trial is the gigantic expense of such a trial -- about 30 million bucks if I remember correctly.
That's why it makes utter sense for the Brilacidin-UP and Brilacidin-OM trials to be done first -- they are, relatively speaking, cheap, fast, and easy (well, okay, I don't consider daily enemas to be "easy" for the patient, but for those running the clinical trial, it's a lot easier than having to get a patient in every day for an IV).